Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02596477 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Vepoloxamer in Chronic Heart Failure
A Phase 2 study, sponsored by Mast Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02596477: Clinical Trial Phase 2 study, sponsored by Mast Therapeutics.
NCT02596477 is a Phase 2 study that was terminated before completion, run by Mast Therapeutics. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02596477, a Phase 2 study, was terminated before completion, sponsored by Mast Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether vepoloxamer can provide a blood chemical marker and functional benefit to damaged heart muscle cells. This will be evaluated by measurement of blood-based laboratory markers, exercise tolerance, and echocardiograms. In addition, the safety and blood levels of vepoloxamer in subjects with chronic heart failure will be evaluated.
Interventions
- DRUG Vepoloxamer
- OTHER 5% dextrose in water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-10 |
| Phase | Phase 2 |
Why NCT02596477 stopped before completion
NCT02596477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Vepoloxamer is the first listed.
NCT02596477 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02596477 about?
NCT02596477 is a clinical study titled "Evaluation of Vepoloxamer in Chronic Heart Failure". The purpose of this study is to evaluate whether vepoloxamer can provide a blood chemical marker and functional benefit to damaged heart muscle cells. This will be evaluated by measurement of blood-based laboratory markers, exercise tolerance, and echocardiograms. In addition, the safety and blood l...
What is the current status of trial NCT02596477?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2015-10.
What interventions are being tested in trial NCT02596477?
The interventions under investigation include: Vepoloxamer (DRUG), 5% dextrose in water (OTHER).
Who is sponsoring clinical trial NCT02596477?
This trial is sponsored by Mast Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02596477's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia